Genetic GHSR deficiency and LEAP2 treatment enhance the glucose-lowering effects of liraglutide in male mice in a metabolic state-dependent manner
Life Sciences · 2026-12 · 406 · 124754
DOI: 10.1016/j.lfs.2026.124754 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Sciences, 2026-12. Verfasst von Daniela A Cassano und 13 weiteren Autor:innen. Beteiligte Einrichtung: Multidisciplinary Institute of Cell Biology [IMBICE, Argentine Research Council (CONICET) and Scientific Research Commission, Province of Buenos Aire…. Hauptthemen laut MEDLINE: Liraglutide, Receptors, Ghrelin, Blood Glucose, Hypoglycemic Agents. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH, Qatar National Research Fund, Novo Nordisk Haemophilia & Haemoglobinopathies Foundation.
Abstract (Originalsprache)
AIMS: Liraglutide is a glucagon-like peptide-1 receptor (GLP-1R) agonist that lowers glycemia and is used to treat type 2 diabetes (T2D) and obesity. Activation of the growth hormone secretagogue receptor (GHSR) increases glycemia. We aimed to determine whether GHSR inhibition enhances the glucose-lowering effects of liraglutide. MATERIALS AND METHODS: We investigated the acute glucose-lowering effects of liraglutide in mice with genetic GHSR deletion or pharmacological GHSR blockade under fed, fasting, and postprandial conditions. We also examined the potential cellular basis of this interaction in murine islets using transcriptomic and immunolabeling approaches and in human pancreatic tissue using a publicly available transcriptomic dataset. KEY FINDINGS: Liraglutide similarly reduced glycemia in ad libitum-fed GHSR-null and control mice. Following food deprivation, liraglutide more effectively attenuated postprandial increases in glycemia in male, but not female, GHSR-null mice than in control mice. Liraglutide reduced glycemia in fasted GHSR-null male mice but not in WT males. In male mice, pretreatment with a LEAP2 (liver-expressed antimicrobial peptide 2) analog, an endogenous GHSR antagonist and inverse agonist, enhanced the glucose-lowering effects of liraglutide under postprandial and fasting conditions. GHSR and GLP-1R showed limited co-expression in murine islets. In human islets, their co-expression was also limited and enriched in δ-cells, but was also detected in β-cells, where the proportion of GHSR+/GLP-1R+ cells was higher in donors with T2D. SIGNIFICANCE: GHSR inhibition enhances liraglutide's glucose-lowering effects in a sex-dependent manner, highlighting GHSR as a potential target to improve GLP-1R agonist efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Multidisciplinary Institute of Cell Biology [IMBICE, Argentine Research Council (CONICET) and Scientific Research Commission, Province of Buenos Aires (CIC-PBA), National University of La Plata], La Plata, Buenos Aires,…
- Center for Hypothalamic Research, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
- Institut des Biomolécules Max Mousseron, Univ Montpellier, CNRS, ENSCM, Montpellier, France.
- Department of Basic Medical Sciences, Qatar University, Doha, Qatar.
- IGF, Univ Montpellier, CNRS, INSERM, Montpellier, France.
- Department of Surgical Sciences, Functional Pharmacology and Neuroscience, University of Uppsala, Uppsala, Sweden; Instituto de Desarrollo e Investigaciones Pediátricas [IDIP; Children's Hospital HIAEP "Sor María Ludovi…
Förderung
- NIH
- Qatar National Research Fund
- Novo Nordisk Haemophilia & Haemoglobinopathies Foundation
- STINT
- Fund for Scientific and Technological Research
Zitieren
APA
Cassano, D. A., Fernandez, G., Cornejo, M. P., Sheybani-Deloui, S., Aguggia, J., Cantel, S., Fehrentz, J. A., Habib, A. M., Rolland, L., Ravier, M. A., Andreoli, M. F., Zigman, J. M., Schiöth, H. B., & Perello, M. (2026). Genetic GHSR deficiency and LEAP2 treatment enhance the glucose-lowering effects of liraglutide in male mice in a metabolic state-dependent manner. Life Sciences, 406, 124754. https://doi.org/10.1016/j.lfs.2026.124754
Vancouver
Cassano DA, Fernandez G, Cornejo MP, Sheybani-Deloui S, Aguggia J, Cantel S, et al. Genetic GHSR deficiency and LEAP2 treatment enhance the glucose-lowering effects of liraglutide in male mice in a metabolic state-dependent manner. Life Sciences. 2026;406:124754. doi:10.1016/j.lfs.2026.124754
BibTeX
@article{Cassano2026,
author = {Cassano, Daniela A and Fernandez, Gimena and Cornejo, María P and Sheybani-Deloui, Sepideh and Aguggia, Julieta and Cantel, Sonia and Fehrentz, Jean-Alain and Habib, Abdella M and Rolland, Laura and Ravier, Magalie A and Andreoli, María F and Zigman, Jeffrey M and Schiöth, Helgi B and Perello, Mario},
title = {Genetic GHSR deficiency and LEAP2 treatment enhance the glucose-lowering effects of liraglutide in male mice in a metabolic state-dependent manner},
journal = {Life Sciences},
year = {2026},
volume = {406},
pages = {124754},
doi = {10.1016/j.lfs.2026.124754}
}
EUVIMED